RxDoctor Payments Data

Charles Comfort, MD

Internal Medicine · Mazon, ILNPI 1861484321

Payments from drug & device makers

$736in general payments, 2019–2025

Across 41 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$232
  • AstraZeneca$198
  • Boehringer Ingelheim$115
  • E.r. Squibb & Sons, L.L.C.$66
  • Novo Nordisk$43
  • Otsuka America Pharmaceutical, Inc.$38
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$736 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$56,618
Medicare patients
215
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$81,450
OzempicSemaglutide45$50,510
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,747
XareltoRivaroxaban11$8,481
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,730
Incruse ElliptaUmeclidinium Bromide12$4,722
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,929
Albuterol Sulfate HfaAlbuterol Sulfate130$3,489
SymbicortBudesonide/Formoterol Fumarate15$3,466
Potassium Chloride138$3,293
Levothyroxine Sodium183$3,161
Losartan Potassium217$2,843
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen81$2,204
Celecoxib53$2,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$50,51045 claims
AstraZenecaBreztri Aerosphere, Symbicort$198$20,27534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Mazon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →